The Journal of Immunology, Vol 155, Issue 2 1000-1009, Copyright © 1995 by American Association of Immunologists

ARTICLES

Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes

AC Tran, D Zhang, R Byrn and MR Roberts
Cell Genesys, Foster City, CA 94404, USA.

Chimeric receptors in which a signaling component of the TCR complex such as zeta is fused directly to the ligand binding domain of a heterologous receptor or Ab have been shown to redirect the specific effector activity of T lymphocytes. We previously described the ability of two classes of such chimeric zeta-receptors bearing extracellular domains derived from either the HIV receptor CD4 (CD4 zeta) or an HIV- specific single chain Ab to redirect primary human CD8+ T cells to kill HIV-infected T cells. In this report we demonstrate that human NK cells can be genetically modified to express high levels of CD4 zeta using retroviral transduction. The CD4 zeta chimeric receptor is biochemically active, as cross-linking of CD4 zeta on NK cells results in tyrosine phosphorylation of CD4 zeta and multiple cellular proteins. More importantly, the CD4 zeta chimeric receptor is functionally active and can direct NK cells to specifically and efficiently lyse either NK- resistant tumor cells expressing the relevant ligand, gp120, or CD4+ T cells infected with HIV. These results show that human NK cells can be readily activated via zeta-based chimeric receptors to target both tumor and virally infected cells, and suggest a novel approach to the treatment of disease.

This article has been cited by other articles:

				H. J. Pegram, J. T. Jackson, M. J. Smyth, M. H. Kershaw, and P. K. Darcy Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo J. Immunol., September 1, 2008; 181(5): 3449 - 3455. [Abstract] [Full Text] [PDF]

				A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination J. Leukoc. Biol., July 1, 2008; 84(1): 27 - 49. [Abstract] [Full Text] [PDF]

				H. I. McFarland, S. A. Hansal, D. I. Morris, D. W. McVicar, P. E. Love, and A. S. Rosenberg Signaling through MHC in transgenic mice generates a population of memory phenotype cytolytic cells that lack TCR Blood, June 1, 2003; 101(11): 4520 - 4528. [Abstract] [Full Text] [PDF]

				W. Y. Lin and M. R. Roberts Developmental dissociation of T cells from B, NK, and myeloid cells revealed by MHC class II-specific chimeric immune receptors bearing TCR-zeta or FcR-gamma chain signaling domains Blood, September 26, 2002; 100(8): 3045 - 3048. [Abstract] [Full Text] [PDF]

				C. Uherek, T. Tonn, B. Uherek, S. Becker, B. Schnierle, H.-G. Klingemann, and W. Wels Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction Blood, July 30, 2002; 100(4): 1265 - 1273. [Abstract] [Full Text] [PDF]

				N. M. Haynes, M. B. Snook, J. A. Trapani, L. Cerruti, S. M. Jane, M. J. Smyth, and P. K. Darcy Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-{{zeta}} vs Fc{{epsilon}}RI-{{gamma}} J. Immunol., January 1, 2001; 166(1): 182 - 187. [Abstract] [Full Text] [PDF]

				T. L. Geiger, D. Leitenberg, and R. A. Flavell The TCR {zeta}-Chain Immunoreceptor Tyrosine-Based Activation Motifs Are Sufficient for the Activation and Differentiation of Primary T Lymphocytes J. Immunol., May 15, 1999; 162(10): 5931 - 5939. [Abstract] [Full Text] [PDF]

				M. R. Roberts, K. S. Cooke, A.-C. Tran, K. A. Smith, W. Y. Lin, M. Wang, T. J. Dull, D. Farson, K. M. Zsebo, and M. H. Finer Antigen-Specific Cytolysis by Neutrophils and NK Cells Expressing Chimeric Immune Receptors Bearing {zeta} or {gamma} Signaling Domains J. Immunol., July 1, 1998; 161(1): 375 - 384. [Abstract] [Full Text] [PDF]

				S. Nagashima, R. Mailliard, Y. Kashii, T. E. Reichert, R. B. Herberman, P. Robbins, and T. L. Whiteside Stable Transduction of the Interleukin-2 Gene Into Human Natural Killer Cell Lines and Their Phenotypic and Functional Characterization In Vitro and In Vivo Blood, May 15, 1998; 91(10): 3850 - 3861. [Abstract] [Full Text] [PDF]

				K. M. Hege, K. S. Cooke, M. H. Finer, K. M. Zsebo, and M. R. Roberts Systemic T Cell-independent Tumor Immunity after Transplantation of Universal Receptor-modified Bone Marrow into SCID Mice J. Exp. Med., December 15, 1996; 184(6): 2261 - 2270. [Abstract] [Full Text] [PDF]

				M. H. Kershaw, P. K. Darcy, M. D. Hulett, P. M. Hogarth, J. A. Trapani, and M. J. Smyth Redirected Cytotoxic Effector Function. REQUIREMENTS FOR EXPRESSION OF CHIMERIC SINGLE CHAIN HIGH AFFINITY IMMUNOGLOBULIN E RECEPTORS J. Biol. Chem., August 30, 1996; 271(35): 21214 - 21220. [Abstract] [Full Text] [PDF]